CNIO researchers discover that a protein that facilitates DNA repair may potentiate chemotherapy
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) CNIO researchers have found out how PrimPol protein helps the cell to survive the damage caused by chemotherapy and plan to use this knowledge to enhance cancer treatments. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 15, 2021 Category: Cancer & Oncology Source Type: news

Model suggests surgery should precede chemotherapy for select patients with ovarian cancer
(NYU Langone Health / NYU Grossman School of Medicine) Certain patients with an aggressive form of ovarian cancer have a better chance of a cure through surgical removal of their tumor before chemotherapy instead of the reverse, a new study shows. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 14, 2021 Category: Cancer & Oncology Source Type: news

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefin...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLC
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves margetuximab for metastatic HER2-positive breast cancer
On December 16, 2020, FDA approved margetuximab-cmkb (MARGENZA, MacroGenics) in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Breath Test Predicts Immunotherapy Response to Mesothelioma
Researchers in the Netherlands are touting a novel breath test for mesothelioma patients to better predict response to the immunotherapy combination of nivolumab and ipilimumab that was approved recently for first-line treatment of the disease. They believe exhaled breath analysis using electronic technology – known as eNose – can differentiate between responders and nonresponders before treatment begins, saving many patients from unnecessary side effects. There currently are no biomarkers for mesothelioma that can accurately predict the effectiveness of these types of immunotherapy drugs, known as immune...
Source: Asbestos and Mesothelioma News - June 10, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer
FDA granted accelerated approval to amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 10, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves nivolumab in combination with chemotherapy for metastatic gastric cancer and esophageal adenocarcinoma
Hematology / Oncology (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 10, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

The 10 Most Important Health Breakthroughs You Missed During the Pandemic
While most eyes were on COVID-19, researchers have also made groundbreaking advancements in other fields. Here’s a look. The other big vaccine news Public-health officials have long sought a vaccine against malaria, which infects up to 600 million people a year and kills 400,000, mostly children. This year, there was dramatic prog­ress toward that goal. In a study of 450 children in Burkina Faso, published in the Lancet in April, researchers reported that a new malaria vaccine, called R21, is 77% effective—just clearing the World Health Organization’s 75% efficacy standard. However, the sample gro...
Source: TIME: Health - June 10, 2021 Category: Consumer Health News Authors: Jeffrey Kluger Tags: Uncategorized COVID-19 feature Innovation Magazine Source Type: news

Kurome Therapeutics closes $15 million Series A financing
(CincyTech) The funding will support the pre-clinical advancement of dual IRAK1/4 and panFLT3 inhibitors to target cancer cells that evade the effects of both targeted therapy and chemotherapy drugs via adaptive resistance mechanisms, having co-opted IRAK1/4-mediated immune signaling pathways to survive. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 10, 2021 Category: Cancer & Oncology Source Type: news

Chemotherapy/Local Excision Avoids Proctectomy in Rectal Cancer Chemotherapy/Local Excision Avoids Proctectomy in Rectal Cancer
Chemotherapy and local excision led to organ preservation in over half of early-stage rectal cancer patients in a small study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 8, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Finding the weak points in radiation-resistant pancreatic cancer cells
(The National Institutes for Quantum and Radiological Science and Technology) Pancreatic cancer is one of the deadliest cancer subtypes not just because it is difficult to diagnose early, but because it is inherently resistant to chemotherapy and radiotherapy. In a recent study, scientists from Japan investigated the relationship that exists between the radiation resistance of pancreatic cancer cells, the natural cell cycle, and a cellular mechanism called autophagy, or " self-digestion. " Their results pave the way for novel radiosensitizers and improved therapeutic strategies for resistant cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 8, 2021 Category: Cancer & Oncology Source Type: news

Pfizer biopharmaceutical company execs function like REPEAT OFFENDER criminals in the fraudulent marketing of deadly drugs and vaccines
(Natural News) Did you know that Pfizer is the largest healthcare fraudster company ever? They focus on making chemical-based medicines that don’t work and cause harm, like chemotherapy and vaccines, and then they settle court and fraud cases with billions of dollars, with just a fraction of the money they make from selling them. In... (Source: NaturalNews.com)
Source: NaturalNews.com - June 7, 2021 Category: Consumer Health News Source Type: news

Covid-19 vaccine maker Johnson Johnson has a LONG history of crimes, fines and violations in the medical "product" business
(Natural News) How about we make the big corporations pay “reparations” for health, medical and human life “damages” for all their years of besieging Americans with toxic products and treatments, including vaccines, chemotherapy and thousands of personal care products? Let’s start with the big guns, like J&J. Johnson & Johnson already had to pay $2.2... (Source: NaturalNews.com)
Source: NaturalNews.com - June 6, 2021 Category: Consumer Health News Source Type: news

Practice Halt: No Benefit in Cervical Cancer With Adjuvant Chemo Practice Halt: No Benefit in Cervical Cancer With Adjuvant Chemo
Adjuvant chemotherapy did not improve survival and was associated with significantly higher toxicity.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Immunotherapy Likely New Standard in Advanced Esophageal Cancer Immunotherapy Likely New Standard in Advanced Esophageal Cancer
Nivolumab with chemotherapy or nivolumab with ipilimumab improved overall survival as compared with standard chemotherapy in advanced ESCC.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New Drug Toripalimab Improves Survival in Nasopharyngeal Cancer New Drug Toripalimab Improves Survival in Nasopharyngeal Cancer
Improved survival in a phase 3 trial where the new drug was added onto chemotherapy could move immunotherapy to the first line, say experts.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Immunotherapy Combo Now Approved for First-Line Mesothelioma in EU Immunotherapy Combo Now Approved for First-Line Mesothelioma in EU
Nivolumab plus ipilimumab showed superior overall survival versus standard-of-care chemotherapy in patients with unresectable malignant mesothelioma.News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

New tech predicts chemotherapy effectiveness after one treatment
(Washington University in St. Louis) Interdisciplinary team finds combining certain data after a patient's first treatment can predict how a tumor will respond to chemotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 3, 2021 Category: Cancer & Oncology Source Type: news

New findings offer improved therapy of early-stage, BRCA mutation-associated breast cancer
(Houston Methodist) A new treatment with potential to improve the outcomes for patients with hereditary BRCA mutations and high-risk, early-stage breast cancer appeared June 3 in the New England Journal of Medicine and will be presented June 6 at the 2021 ASCO Annual Meeting. These results represent the first time a PARP inhibitor has been shown to significantly reduce the risk of breast cancer returning in high-risk patients following completion of standard chemotherapy, surgery and radiation therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 3, 2021 Category: Cancer & Oncology Source Type: news

ASCO: COVID - 19 Infections, Deaths Not Up With   Breast Cancer Chemo
Risk for death following SARS - CoV - 2 infection increased with advanced - stage disease, higher comorbidity, but not receipt of chemotherapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 2, 2021 Category: Cancer & Oncology Tags: Gynecology, Infections, Oncology, Pharmacy, Conference News, Source Type: news

ASCO: COVID-19 Infections, Deaths Not Up With   Breast Cancer Chemo
WEDNESDAY, June 2, 2021 -- Patients receiving chemotherapy for breast cancer do not have an increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or mortality, according to a study scheduled to be presented at the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 2, 2021 Category: Pharmaceuticals Source Type: news

Soon NO JOBS available for the unvaccinated except for carrying the dead bodies of the previously vaccinated
(Natural News) When you get cancer really bad and the cells are taking over your vital organs or brain, and once you’ve been given several rounds of chemotherapy, surgery and radiation, and nothing’s changing, the doctors send you home to die. That’s because the mechanism in your cells that controls the reproduction is broken in... (Source: NaturalNews.com)
Source: NaturalNews.com - June 2, 2021 Category: Consumer Health News Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

BeyondSpring Announces U.S. FDA Acceptance And Priority Review Of New Drug Application For Plinabulin And G-CSF Combination For The Prevention Of Chemotherapy-Induced Neutropenia (CIN)
NEW YORK, June 01, 2021 (GLOBE NEWSWIRE)— BeyondSpring Inc. (the“Company” or“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies,... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - June 1, 2021 Category: Drugs & Pharmacology Source Type: news

Clinician FAQs and guidance on covid-19 vaccine for patients receiving systemic anti-cancer therapy (SACT). version 4.0, UK Chemotherapy Board
This document has been revised to include updated information on the Pfizer/BioNTech COVID-19 vaccine, Oxford University/AstraZeneca vaccine and Moderna vaccine, reflecting updated guidance from JCVI and the MHRA. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 28, 2021 Category: Consumer Health News Source Type: news

Stem cell drugs surprise researchers: Could lead to better drugs in the future
(University of Copenhagen - The Faculty of Health and Medical Sciences) Chemotherapy destroys stem cells, which then cannot develop into immune cells and become part of the body's defences. There are drugs that can remedy this, but previously we did not know exactly how these drugs worked. Now, a study conducted in mice by researchers at the University of Copenhagen details their function providing new knowledge that may improve stem cell transplantation and lead to better drug design in the future. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 28, 2021 Category: Biology Source Type: news

ECOG-ACRIN research highlights at ASCO 2021
(ECOG-ACRIN Cancer Research Group) Platinum chemotherapy fails for triple-negative breast cancer, basal-like subtype. The first racially diverse trial to look at severe joint pain from aromatase inhibitors shows more postmenopausal Black and Asian women with early breast cancer developed this common/significant syndrome. Less intense therapy for HPV-associated throat cancer shows outstanding three-year survival and quality of life. Inflammation biomarker links to distant recurrence of HER2-negative early breast cancer. Joseph A. Sparano receives ASCO's 2021 Gianni Bonadonna Breast Cancer Award and Lecture. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 28, 2021 Category: Cancer & Oncology Source Type: news

Black Patients More Likely to Die From Triple - Negative Breast Cancer
Higher mortality risk partially explained by disparities in Black patients'receipt of surgery and chemotherapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 27, 2021 Category: Cancer & Oncology Tags: Gynecology, Oncology, Surgery, Journal, Source Type: news

Cell mechanics research is making chemotherapy friendlier
(The Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences) Malignant tumour cells undergo mechanical deformation more easily than normal cells, allowing them to migrate throughout the body. The mechanical properties of prostate cancer cells treated with the most commonly used anti-cancer drugs have been investigated at the Institute of Nuclear Physics of the Polish Academy of Sciences in Cracow. According to the researchers, current drugs can be used more effectively and at lower doses. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 27, 2021 Category: Cancer & Oncology Source Type: news

Memorial Sloan Kettering Opening New Mesothelioma Clinical Trial
Memorial Sloan Kettering Cancer Center in New York City will begin recruiting soon for its latest clinical trial involving patients with malignant pleural mesothelioma and the expanded use of immunotherapy. The single-center, phase I study will explore the effectiveness of pembrolizumab in combination with intensity-modulated pleural radiation therapy, known as IMPRINT, in treating unresectable disease. Pembrolizumab, also known by the brand name Keytruda, was approved by the U.S. Food and Drug Administration in 2020 for treatment of a small subset of mesothelioma patients. As a well-known immunotherapy drug, pemb...
Source: Asbestos and Mesothelioma News - May 26, 2021 Category: Environmental Health Authors: Matt Bardsley Source Type: news

New Era for Cervical Cancer With Cemiplimab'Impressive' Results New Era for Cervical Cancer With Cemiplimab'Impressive' Results
The superiority of cemiplimab over chemotherapy in improving overall survival in patients with recurrent or metastatic cervical cancer was hailed as"practice changing."Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 26, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Long-Term ERLEADA ® (apalutamide) Patient-Reported Outcomes Data in Metastatic Castration-Sensitive Prostate Cancer Demonstrate Maintenance of Health-Related Quality of Life for Patients
May 26, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced patient-reported outcomes (PRO) data from the pre-specified final analysis of the Phase 3 TITAN study in patients with metastatic castration-sensitive prostate cancer (mCSPC). The TITAN study previously demonstrated statistically significant improvement in overall survival (OS) after a median follow-up of 44 months in patients receiving ERLEADA® plus androgen deprivation therapy (ADT).1 The new PRO data showed that the addition of ERLEADA® to ADT maintained patients’ health-related quality of lif...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Good bacteria can temper chemotherapy side effects
(Northwestern University) A new Northwestern University study found that specific types of gut bacteria can protect other good bacteria from cancer treatments -- mitigating harmful, drug-induced changes to the gut microbiome. By metabolizing chemotherapy drugs, the protective bacteria could temper short- and long-term side effects of treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 26, 2021 Category: Cancer & Oncology Source Type: news

Novel way by NUS scientists to predict chemotherapy resistance in ovarian cancer patients
(National University of Singapore) Researchers from the National University of Singapore have found a way to predict if ovarian cancer patients will be resistant to chemotherapy. By using " automated " microscopy, they identified a protein that indicates the resistance of ovarian cancer cells to platinum chemotherapy. This breakthrough could improve the survival rate of ovarian cancer patients, as other treatments may be administered early. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 26, 2021 Category: Cancer & Oncology Source Type: news

Dartmouth and Dartmouth-Hitchcock Cancer Researchers Discover Cutting-Edge Approach to Fighting a Form of Deadly Cancer
Researchers at Norris Cotton Cancer Center have developed a way to predict chemotherapy response to tailor treatments for pancreatic cancer patients. (Source: News at Dartmouth Medical School)
Source: News at Dartmouth Medical School - May 25, 2021 Category: Hospital Management Authors: NonPerson Geisel Web Service Acct Tags: News Press Release Research Norris Cotton Cancer Center Source Type: news

MD Anderson Examines Aggressive Mesothelioma Surgery in Latest Study
A retrospective study involving two decades of pleural mesothelioma patients at the heralded University of Texas MD Anderson Cancer Center failed to demonstrate a definitive survival advantage to support regular use of extrapleural pneumonectomy surgery. The most aggressive surgery possible for this type of mesothelioma – once the surgery of choice – showed no clear benefit over a more conservative procedure. When compared to the less-aggressive, lung-sparing pleurectomy and decortication surgery, EPP had a much higher perioperative mortality rate and a shorter median survival. “In comparison, we...
Source: Asbestos and Mesothelioma News - May 25, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy
Basel, 25 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. (Source: Roche Media News)
Source: Roche Media News - May 25, 2021 Category: Pharmaceuticals Source Type: news

European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy
Basel, 25 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. (Source: Roche Investor Update)
Source: Roche Investor Update - May 25, 2021 Category: Pharmaceuticals Source Type: news

European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. (Source: World Pharma News)
Source: World Pharma News - May 25, 2021 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Predicting chemotherapy response and tailoring treatments for pancreatic cancer patients
(Dartmouth-Hitchcock Medical Center) After discovering critical epigenetic elements involved in chemotherapy resistance of pancreatic cancer, researchers from Dartmouth's and Dartmouth-Hitchcock's Norris Cotton Cancer Center have invented a novel biomarker platform that rapidly assesses these elements as a means to predict chemotherapy response and select pancreatic cancer patients who are most likely to benefit from traditional chemotherapy versus possible alternate epigenetic therapy. This technology introduces the first-ever epigenetic precision medicine approach to pancreatic cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 24, 2021 Category: International Medicine & Public Health Source Type: news

RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.[1] RYBREVANTTM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC t...
Source: Johnson and Johnson - May 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer
FDA granted accelerated approval to amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 21, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Pivotal Phase III data at ASCO show Roche ’s Tecentriq helps certain people with early lung cancer live significantly longer without their disease returning
Basel, 20 May 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced interim results from the Phase III IMpower010 study, showing for the first time that treatment with Tecentriq® (atezolizumab) following surgery and chemotherapy reduced the risk of disease recurrence or death (disease-free survival; DFS) by 34% (hazard ratio [HR]=0.66, 95% CI: 0.50–0.88) in people with Stage II-IIIA non-small cell lung cancer (NSCLC), whose tumours express PD-L1≥1%, compared with best supportive care (BSC). In this population, median DFS was not yet reached for Tecentriq compared with 35.3 months for BSC. (Source: Roche Media News)
Source: Roche Media News - May 20, 2021 Category: Pharmaceuticals Source Type: news

Pivotal Phase III data at ASCO show Roche ’s Tecentriq helps certain people with early lung cancer live significantly longer without their disease returning
Basel, 20 May 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced interim results from the Phase III IMpower010 study, showing for the first time that treatment with Tecentriq® (atezolizumab) following surgery and chemotherapy reduced the risk of disease recurrence or death (disease-free survival; DFS) by 34% (hazard ratio [HR]=0.66, 95% CI: 0.50–0.88) in people with Stage II-IIIA non-small cell lung cancer (NSCLC), whose tumours express PD-L1≥1%, compared with best supportive care (BSC). In this population, median DFS was not yet reached for Tecentriq compared with 35.3 months for BSC. (Source: Roche Investor Update)
Source: Roche Investor Update - May 20, 2021 Category: Pharmaceuticals Source Type: news

Updated Amivantamab and Lazertinib Combination Data Demonstrate Durable Responses and Clinical Activity for Osimertinib-Relapsed Patients with EGFR-Mutated Non-Small Cell Lung Cancer
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated data from the Phase 1 CHRYSALIS study showing treatment with amivantamab in combination with lazertinib led to a median duration of response (DOR) of 9.6 months in chemotherapy-naïve patients with non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib.[1] These data, which will be presented in an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual ...
Source: Johnson and Johnson - May 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Chemotherapy-Induced Nausea and Vomiting: Developing Drugs for Prevention Guidance for Industry
Chemotherapy-Induced Nausea and Vomiting: Developing Drugs for Prevention Guidance for Industry - Clinical Medicine (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 19, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Combination therapy achieves high rates of response for patients with ALL
(University of Texas M. D. Anderson Cancer Center) A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), according to researchers at The University of Texas MD Anderson Cancer Center. The study may support a regimen to produce complete remission with front-line therapy, without the increased risks associated with systemic chemotherapy or a stem cell transplant. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 19, 2021 Category: Cancer & Oncology Source Type: news

Impact of Tumor Size on pCR Rates in TNBC After Chemotherapy Impact of Tumor Size on pCR Rates in TNBC After Chemotherapy
What impact might tumor size have on pathological complete response rates in triple negative breast cancer patients receiving neoadjuvant chemotherapy?Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 17, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

BERENICE: Further Evidence of Heart Safety of Dual HER2 Blockade BERENICE: Further Evidence of Heart Safety of Dual HER2 Blockade
Final results were presented at ESMO Breast Cancer 2021 on dual HER2 blockade with pertuzumab and trastuzumab on top of anthracycline-based neoadjuvant chemotherapy for early-stage breast cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 14, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news